Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.42 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746614 | 1.00 | NTRK1 (0.47) | NTRK1CSF1RPLAUGAAMAPT | |
| SCHEMBL23044049 | 0.91 | EIF2AK3 (0.51) | NTRK1CSF1RGAAFLT3RIPK1 | |
| SCHEMBL29746539 | 0.91 | EIF2AK3 (0.51) | NTRK1CSF1RGAAFLT3RIPK1 | |
| SCHEMBL23043903 | 0.85 | FLT3 (0.50) | NTRK1CSF1RFLT3EIF2AK3MET | |
| SCHEMBL29684025 | 0.85 | FLT3 (0.55) | NTRK1CSF1RFLT3EIF2AK3EIF2S1 | |
| SCHEMBL23043916 | 0.85 | FLT3 (0.55) | NTRK1CSF1RFLT3EIF2AK3EIF2S1 | |
| SCHEMBL29746861 | 0.85 | EIF2AK3 (0.54) | NTRK1FLT3RIPK1EIF2AK3EIF2S1 | |
| SCHEMBL23043888 | 0.85 | RIPK1 (0.53) | NTRK1FLT3RIPK1EIF2AK3EIF2S1 | |
| SCHEMBL23044652 | 0.85 | EIF2AK3 (0.54) | NTRK1FLT3RIPK1EIF2AK3EIF2S1 | |
| SCHEMBL29746729 | 0.85 | RIPK1 (0.53) | NTRK1FLT3RIPK1EIF2AK3EIF2S1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | claimed |
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114710956-A | PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | 希伯塞尔股份有限公司 | 2022-07-05 | — | — | CN | claimed |
| WO-2021231788-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114710956-A | PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | 希伯塞尔股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| WO-2021231788-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | NTRK1 2842/4885CSF1R 3203/4885PLAU 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.